(L to R) Dr. Parisa Zamiri, Tom Reilly and Anand Sundaram.

MELBOURNE, Australia and PRINCETON, N.J.—Opthea Limited (ASX/NASDAQ: OPT), a clinical-stage biopharmaceutical company developing novel therapies to treat progressive retinal diseases, including wet age-related macular degeneration (wet AMD), has announced three senior hires, including Dr. Parisa Zamiri as chief medical officer, Tom Reilly as chief financial officer and Anand Sundaram as vice president of marketing. “Opthea is at an inflection point with the anticipated sozinibercept Phase 3 topline data readouts in 2025 and subsequent U.S. and other regulatory submissions around the world,” said Frederic Guerard, PharmD, chief executive officer, Opthea.

“The appointments of Dr. Parisa Zamiri as chief medical officer, Tom Reilly as chief financial officer and Anand Sundaram as vice president of marketing further deepen our team’s expertise in retina, strengthen our leadership in finance and continue to advance Opthea’s commercial readiness,” Guerard said.

As CMO, effective October 7, 2024, Dr. Zamiri will oversee clinical development and operations, regulatory and medical affairs, as well as biometrics. Dr. Zamiri is a physician-scientist with deep expertise in drug discovery and development. She is an ophthalmologist by training, with clinical experience in medical retina, immunology and inflammation. She most recently served as the chief medical officer at Complement Therapeutics and previously at Graybug Vision. Prior to that, she served as vice president, global head of clinical development and therapeutic area head for ophthalmology at Novartis Pharmaceuticals.

 
Reilly’s appointment as CFO is effective October 28, 2024, according to the company. He succeeds Daniel Geffken, who was the interim CFO. Reilly has more than 25 years of experience in building and leading finance and administration teams at life sciences companies, both in the United States and globally. Before joining Opthea, Reilly served as chief financial officer and head of human resources of Amarin Corporation, supporting the commercial expansion of the company’s lead asset in cardiovascular disease.

Sundaram’s appointment as VP of marketing is effective October 14, 2024, according to the announcement. Sundaram brings more than a decade of commercial experience in brand strategy, marketing, access and reimbursement, digital and sales across retina, cardiovascular and infectious disease to Opthea.